Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Investing > FTSE 100 subdued as pharma stocks weigh
    Investing

    FTSE 100 subdued as pharma stocks weigh

    Published by Wanda Rich

    Posted on November 15, 2024

    2 min read

    Last updated: January 28, 2026

    The image illustrates the FTSE 100 index's subdued performance, influenced by declining shares of AstraZeneca and GSK. This reflects concerns over the UK economy's contraction in September, impacting investor sentiment.
    FTSE 100 index performance impacted by falling AstraZeneca and GSK stocks - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:GDPUK economypharmaceutical marketstock marketinvestment

    Quick Summary

    (Reuters) – The main UK stock indexes were subdued on Friday, with losses in AstraZeneca and GSK weighing on the blue-chip

    (Reuters) – The main UK stock indexes were subdued on Friday, with losses in AstraZeneca and GSK weighing on the blue-chip FTSE 100, while data showed Britain’s economy contracted unexpectedly in September.

    Shares of drugmakers AstraZeneca dropped 2.4% and GSK dipped 3.2%, tracking losses in U.S. and European vaccine makers after U.S. President-elect Donald Trump said he had selected Robert F. Kennedy Jr., who has previously spread misinformation on vaccines, to lead the Department of Health and Human Services.

    The FTSE 100, however, edged up 0.1%, helped by a rebound in mining stocks from losses earlier in the week.

    The midcap FTSE 250 index was flat.

    Britain’s economy contracted unexpectedly in September and growth slowed to a crawl over the third quarter, data showed, an early setback for finance minister Rachel Reeves’ ambitions to kick-start a sustained pickup.

    GDP slipped by 0.1% in monthly terms during September, while economists had forecast an expansion of 0.2%.

    The latest UK GDP figures offered evidence of the chilling effect of a Budget build-up filled with warnings about hard decisions,” said Russ Mould, investment director at AJ Bell.

    On Thursday, Reeves promised a reboot of regulation governing Britain’s “crown jewel” financial industry, which she said had stifled economic growth.

    Land Securities climbed 2% after the commercial property firm forecast annual earnings above market expectations.

    TT Electronics soared 37% after Volex Plc said the British electronic components maker had declined to engage with it and rejected two takeover offers it had submitted.

    Volex, the maker of power products and data connectivity cable, fell about 13%.

    (Reporting by Sruthi Shankar in Bengaluru; Editing by Tasim Zahid)

    Frequently Asked Questions about FTSE 100 subdued as pharma stocks weigh

    1What is GDP?

    Gross Domestic Product (GDP) is the total value of all goods and services produced in a country over a specific time period, used as a broad measure of economic activity.

    2What is the FTSE 100?

    The FTSE 100 is a stock market index that represents the 100 largest companies listed on the London Stock Exchange, reflecting the performance of the UK stock market.

    3What are blue-chip stocks?

    Blue-chip stocks are shares of well-established companies with a history of stable earnings, reliability, and strong performance, often considered safe investments.

    More from Investing

    Explore more articles in the Investing category

    Image for Understanding the Factors Shaping Bitcoin’s Current Market Conditions
    Understanding the Factors Shaping Bitcoin’s Current Market Conditions
    Image for Understanding Investment Management Consulting Services in the U.S. Market
    Understanding Investment Management Consulting Services in the U.S. Market
    Image for The Role of DST Sponsors and Service Providers in Delaware Statutory Trusts
    The Role of DST Sponsors and Service Providers in Delaware Statutory Trusts
    Image for Understanding Self-Directed IRA Structures and Platform Models
    Understanding Self-Directed IRA Structures and Platform Models
    Image for 1031 Exchanges and Delaware Statutory Trusts: What Investors Need to Know
    1031 Exchanges and Delaware Statutory Trusts: What Investors Need to Know
    Image for Excellence in Innovation – Strategic Investment & Economic Transformation Egypt 2025
    Excellence in Innovation – Strategic Investment & Economic Transformation Egypt 2025
    Image for What Is the Average Pension Pot in the UK? (By Age)
    What Is the Average Pension Pot in the UK? (By Age)
    Image for From Money Printing to Market Surge: The Macro Forces Driving Crypto in 2026
    From Money Printing to Market Surge: The Macro Forces Driving Crypto in 2026
    Image for  Millennials Aren’t Ignoring Retirement. They’re Rebuilding It.
    Millennials Aren’t Ignoring Retirement. They’re Rebuilding It.
    Image for BridgeWise Launches FixedWise, the First AI Solution Bringing Granular Bond Intelligence to the European Market
    BridgeWise Launches FixedWise, the First AI Solution Bringing Granular Bond Intelligence to the European Market
    Image for Why Financial Advisors Are Rethinking Gold Allocations
    Why Financial Advisors Are Rethinking Gold Allocations
    Image for From Opaque to Investable: Yaniv Bertele's Blueprint for Transparent Alternatives
    From Opaque to Investable: Yaniv Bertele's Blueprint for Transparent Alternatives
    View All Investing Posts
    Previous Investing PostStocks head south as Fed chair sows rate cut doubts
    Next Investing PostOil dips on bigger-than-expected US crude stockbuild, oversupply concerns